More drugs, vaccines needed for M/XDR-TB

8 April 2009

Health ministers from countries with the greatest burdens of multiple or extreme drug-resistant tuberculosis (M/XDR-TB) have agreed a program to  halt and reverse the global disease epidemic. The leaders met in  Beijing, China, at a three-day event hosted by the World Health  Organization's Director General Margaret Chan and the co-chairman of the  Bill & Melinda Gates Foundation, Microsoft founder Bill Gates. China's  Vice Premier Li Keqiang and representatives of 27 countries with high  burdens of TB were also present.

A package of measures was called for, including: universal access to  M/XDR-TB diagnosis and treatment by 2015; removal of financial barriers  to TB care; sufficient trained and deployed staff; improved laboratory  systems; the development of airborne infection-control policies; a  sufficient supply of high-quality anti-TB drugs; and mechanisms to  ensure availability of TB medicines is regulated.

Mr Gates urged all countries to invest in innovative methods to fight  TB. He said: "every country should feel the urgency, whether it is  suffering from TB or not. Every country is capable of innovation,  whether it has a high-tech economy or not. And every country can adapt  its systems to use the best innovations of others."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight